Business Description
Ultimovacs ASA
ISIN : NO0010851603
Share Class Description:
CHIX:ULTIo: Ordinary SharesCompare
Compare
Traded in other countries / regions
ULTI.NorwayULTIo.Sweden7UM.GermanyULTIo.UK IPO Date
2023-08-31Description
Ultimovacs ASA is a pharmaceutical company involved in developing novel immunotherapies against cancer. Its product candidate is UV1, a peptide-based vaccine inducing T cell responses against the universal cancer antigen telomerase. The company and its proprietary technology are based on preclinical and clinical research on immunotherapies conducted at the Oslo University Hospital.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 51.31 | |||||
| Equity-to-Asset | 0.89 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.02 | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -15.5 | |||||
| 3-Year EPS without NRI Growth Rate | -13.6 | |||||
| 3-Year FCF Growth Rate | -13.7 | |||||
| 3-Year Book Growth Rate | -19 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 58.89 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 11.36 | |||||
| Quick Ratio | 11.36 | |||||
| Cash Ratio | 10.63 | |||||
| Days Payable | 1064.63 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -2.4 | |||||
| Shareholder Yield % | 2.09 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -58.52 | |||||
| ROA % | -49.33 | |||||
| ROIC % | -179.38 | |||||
| ROC (Joel Greenblatt) % | -4511.74 | |||||
| ROCE % | -56.62 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.41 | |||||
| Price-to-Tangible-Book | 0.66 | |||||
| EV-to-EBIT | 0.32 | |||||
| EV-to-EBITDA | 0.32 | |||||
| EV-to-Forward-EBITDA | -18.78 | |||||
| EV-to-FCF | 0.28 | |||||
| Price-to-Net-Current-Asset-Value | 0.67 | |||||
| Price-to-Net-Cash | 0.73 | |||||
| Earnings Yield (Greenblatt) % | 314 | |||||
| FCF Yield % | -226.64 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Ultimovacs ASA Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | |||
| EPS (TTM) (kr) | -4.4 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR (kr) | 0 | ||
| 20-Day SMA (kr) | 100.2 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range (kr) | 100.2 - 100.2 | ||
| Shares Outstanding (Mil) | 34.41 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Ultimovacs ASA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Ultimovacs ASA Stock Events
| Event | Date | Price(kr) | ||
|---|---|---|---|---|
| No Event Data | ||||
Ultimovacs ASA Frequently Asked Questions
What is Ultimovacs ASA(CHIX:ULTIo)'s stock price today?
The current price of CHIX:ULTIo is kr100.20. The 52 week high of CHIX:ULTIo is kr100.20 and 52 week low is kr100.20.
When is next earnings date of Ultimovacs ASA(CHIX:ULTIo)?
The next earnings date of Ultimovacs ASA(CHIX:ULTIo) is 2025-02-13.
Does Ultimovacs ASA(CHIX:ULTIo) pay dividends? If so, how much?
Ultimovacs ASA(CHIX:ULTIo) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers